NEO
NEOGENOMICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$16.42
−1.38%Oct 15, 2026, 11:05 UTC
NEOGENOMICS INC expanded its partnership with Indica Labs, Inc. to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.
Source:Oct 14, 2026, 11:05 UTC
NEOGENOMICS INC said it will report its third-quarter 2026 financial results after the U.S. market close on October 28, 2026.
Source:Oct 6, 2026, 17:54 UTC
NEOGENOMICS INC announced preliminary financial results for the third quarter ended September 30, 2026.
Source:Oct 6, 2026, 17:54 UTC
NEOGENOMICS INC announced an executive succession plan.
Source:Oct 5, 2026, 20:12 UTC
NeoGenomics Inc. appointed Michael Kelly as Lead Independent Director effective January 4, 2027.
Oct 5, 2026, 20:12 UTC
NeoGenomics Inc. Chair of the Board Lynn Tetrault departed at term expiry effective January 4, 2027, succeeded by Michael Kelly.
Oct 5, 2026, 20:12 UTC
NeoGenomics Inc. appointed Tony Zook as Executive Chairman effective January 4, 2027.
Oct 5, 2026, 20:12 UTC
NeoGenomics Inc. appointed Warren Stone as Chief Executive Officer and board member effective January 4, 2027.
Aug 28, 2026, 09:57 UTC
NeoGenomics Inc. shares rose over 7% to a 52-week high of $19.76 on August 27, 2026.
Aug 26, 2026, 20:17 UTC
NeoGenomics announced expanded Medicare MolDX coverage for its RaDaR ST MRD assay for immunotherapy treatment response monitoring in late-stage solid tumors.
Source:Aug 12, 2026, 21:59 UTC
NeoGenomics launched its PanTracer Pro assay and RaDar ST ctDNA assay for advanced cancer testing in 2026.
Source:Jul 28, 2026, 20:05 UTC
NeoGenomics reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 20, 2026, 21:23 UTC
NeoGenomics settled a voluntary disclosure with the Office of Inspector General of the U.S. Department of Health and Human Services.
Source:Jun 25, 2026, 00:00 UTC
NeoGenomics Inc. appointed Carolyn S. Starrett as a Director, effective June 23, 2026.
Jun 22, 2026, 00:00 UTC
NeoGenomics Inc. issued $316.25 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, using part of the proceeds to repurchase $276 million of its existing 2028 convertible notes and entering into capped call transactions.
Jun 17, 2026, 10:00 UTC
NeoGenomics priced an offering of $275 million convertible senior notes.
Source: